Operating Metrics 營運指標
Novartis AG (NVS) Operating Metrics 營運指標
Novartis AG NVS 最近 8 季公司營運 KPI、指標定義、跨期趨勢與官方來源。
資料截至：2026-06-30
最新營運指標
- Kisqali Sales
- $5.86B · 2026-06-30 來源：Novartis AG、Novartis AG、Novartis AG、Novartis AG
- Kesimpta Sales
- $5.04B · 2026-06-30 來源：Novartis AG、Novartis AG、Novartis AG、Novartis AG
- Cosentyx Sales
- $6.9B · 2026-06-30 來源：Novartis AG、Novartis AG、Novartis AG、Novartis AG
- Pluvicto Sales
- $2.46B · 2026-06-30 來源：Novartis AG、Novartis AG、Novartis AG、Novartis AG
- Leqvio Sales
- $1.58B · 2026-06-30 來源：Novartis AG、Novartis AG、Novartis AG、Novartis AG
- Kesimpta Patients Treated Since Launch
- >216 K patients · 2026-06-30 來源：Novartis AG
季度趨勢
| 指標 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 | Q3 FY2024 |
|---|---|---|---|---|---|---|---|---|
| Kisqali Sales | $1.7B | $1.52B | $1.32B | $1.33B | $1.18B | $0.96B | $0.9B | $0.79B |
| Kesimpta Sales | $1.42B | $1.16B | $1.23B | $1.22B | $1.08B | $0.9B | $0.95B | $0.84B |
| Cosentyx Sales | $1.82B | $1.57B | $1.81B | $1.7B | $1.63B | $1.53B | $1.6B | $1.69B |
| Pluvicto Sales | $0.65B | $0.64B | $0.61B | $0.56B | $0.45B | $0.37B | $0.35B | $0.39B |
| Leqvio Sales | $0.48B | $0.45B | $0.34B | $0.31B | $0.3B | $0.26B | $0.22B | $0.2B |
| Kesimpta Patients Treated Since Launch | >216 K patients | >200 K patients | >187 K patients | >155 K patients | — | — | — | — |
資料來源
- Novartis Q2 2026 Condensed Interim Financial Report – Supplementary Data · Novartis AG · 2026-07-21
- Novartis Q1 2026 Condensed Interim Financial Report – Supplementary Data · Novartis AG · 2026-04-28
- Novartis Q4 2025 Condensed Financial Report – Supplementary Data · Novartis AG · 2026-02-04
- Novartis Q3 2025 Condensed Interim Financial Report – Supplementary Data · Novartis AG · 2025-10-28